No abstract

specific research questions. Results: We identified 327 national or regional general oncology registries. Almost each country has databases collecting information on diagnosis and survival data, but databases collecting information on treatment and response to treatment are rare. Interviews revealed that medical records typically collect detailed information on diagnosis, treatment and response, although specific details vary per country. ConClusions: The method tested represents a practical guide for identifying and assessing available RWE-sources. Patient-registries containing detailed data are good sources for RWE gathering, but in countries without such registries, data collection from clinical practice is still a feasible alternative for RWE collection PCN328 What LifeCyCLe MaNageMeNt LessoNs CaN We LearN froM Pd-1 iMMuNo-oNCoLogy theraPies?

the treatment of asthma were not accepted due to comments about population and model input, lack of statistical calculations and size of the incremental effects. Ranibizumab's results for age-related macular degeneration were not accepted because of a wrong comparator, lack of long term data, assumptions on risks and mortality, and uncertainties around health care costs and ICER sensitivity. Finally, ZiNL considered the appropriate use of alglucosidase alfa for Pompe's disease to be unsubstantiated because of the population choice for the ICER calculation and the use of a higher dose than the registered dose which was not supported by scientific data. The outcome results of alglucosidase alfa for cost-effectiveness were accepted, however. ConClusions: Although at T= 0 ZiNL provided feedback regarding the design of the outcome research study, most of ZiNL's comments were on the final methodology used. The outcome research studies were considered to be of mixed quality and the results could often not substantiate the claim of cost-effectiveness and appropriate use.